FDA 批准首个治疗局部晚期、转移性尿路上皮癌的药物。
FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer.
出版信息
Oncology (Williston Park). 2020 Jan 15;34(1):11.
PMID:32645199
Abstract
The FDA approved enfortumab vedotinejfv (Padcev)-the first drug to treat adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) inhibitor and platinum-containing chemotherapy.
摘要
美国食品和药物管理局批准了 enfortumab vedotin jfv（Padcev）——第一种用于治疗先前接受过程序性细胞死亡蛋白 1（PD-1）/程序性死亡配体 1（PD-L1）抑制剂和含铂化疗治疗的局部晚期或转移性尿路上皮癌的成年患者的药物。
Zotero 插件